Cargando…

A novel GLP-1 and FGF21 dual agonist has therapeutic potential for diabetes and non-alcoholic steatohepatitis

BACKGROUND: Fibroblast growth factor 21 (FGF21) has become a promising therapeutic target for metabolic diseases such as type 2 diabetes (T2D), obesity and non-alcoholic steatohepatitis. However, the clinical application of natural FGF21 molecule is limited because of its instability in vitro and sh...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pan, Qi, Lin, Shushan, Li, Yu, Liu, Liang, Li, Xiaoping, Gao, Xianglei, Yan, Jiangyu, Gu, Baohua, Chen, Xiaofeng, Li, Wenjia, Tang, Xinfa, Chen, Chao, Guo, Lixin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7806870/ https://www.ncbi.nlm.nih.gov/pubmed/33421947 http://dx.doi.org/10.1016/j.ebiom.2020.103202

Ejemplares similares

Sustained release of a GLP-1 and FGF21 dual agonist from an injectable depot protects mice from obesity and hyperglycemia
por: Gilroy, C. A., et al.
Publicado: (2020)

Treating nonalcoholic steatohepatitis with antidiabetic drugs: Will GLP-1 agonists end the struggle?
por: Kalogirou, Maria, et al.
Publicado: (2018)

Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes
por: Hartman, Mark L., et al.
Publicado: (2020)

Effects of ALT-801, a GLP-1 and glucagon receptor dual agonist, in a translational mouse model of non-alcoholic steatohepatitis
por: Nestor, John J., et al.
Publicado: (2022)

Aberrant FGFR4 signaling worsens nonalcoholic steatohepatitis in FGF21KO mice
por: Yu, Youxi, et al.
Publicado: (2021)

FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases
por: Tillman, Erik J., et al.
Publicado: (2020)

Agonistic β-Klotho antibody mimics fibroblast growth factor 21 (FGF21) functions
por: Min, Xiaoshan, et al.
Publicado: (2018)

Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
por: Willard, Francis S., et al.
Publicado: (2020)

Special Report: Potential Strategies for Addressing GLP-1 and Dual GLP-1/GIP Receptor Agonist Shortages
por: Whitley, Heather P., et al.
Publicado: (2023)

FGF21 protects against hepatic lipotoxicity and macrophage activation to attenuate fibrogenesis in nonalcoholic steatohepatitis
por: Liu, Cong, et al.
Publicado: (2023)

Propofol Improved Glucose Tolerance Associated with Increased FGF-21 and GLP-1 Production in Male Sprague-Dawley Rats
por: Wu, Chih-Cheng, et al.
Publicado: (2020)

Plasma FGF21 concentrations are regulated by glucose independently of insulin and GLP-1 in lean, healthy humans
por: Solomon, Thomas P.J., et al.
Publicado: (2022)

Metabolic and gut microbiome changes following GLP-1 or dual GLP-1/GLP-2 receptor agonist treatment in diet-induced obese mice
por: Madsen, Mette Simone Aae, et al.
Publicado: (2019)

A Dual GLP-1/GIP Receptor Agonist Does Not Antagonize Glucagon at Its Receptor but May Act as a Biased Agonist at the GLP-1 Receptor
por: Al-Zamel, Noura, et al.
Publicado: (2019)

Clinical Management of Nonalcoholic Steatohepatitis (NASH) With the Use of Thiazolidinediones and the Additive Effect of Thiazolidinediones and a GLP-1 Agonist: Case Series
por: Rojas Ortiz, Valentina, et al.
Publicado: (2021)

Combination of an ACLY inhibitor with a GLP-1R agonist exerts additive benefits on nonalcoholic steatohepatitis and hepatic fibrosis in mice
por: Desjardins, Eric M., et al.
Publicado: (2023)

Effects of Renal Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide
por: Urva, Shweta, et al.
Publicado: (2021)

Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide
por: Urva, Shweta, et al.
Publicado: (2022)

Designing a Dual GLP-1R/GIPR Agonist from Tirzepatide: Comparing Residues Between Tirzepatide, GLP-1, and GIP
por: Wang, Lijing
Publicado: (2022)

GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential
por: Ma, Xiaoxuan, et al.
Publicado: (2021)

GLP-1 receptor agonist as a modulator of innate immunity
por: Chen, Jun, et al.
Publicado: (2022)

Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD
por: Seghieri, Marta, et al.
Publicado: (2018)

FGF19 subfamily members: FGF19 and FGF21
por: Dolegowska, Katarzyna, et al.
Publicado: (2019)

Design of a highly potent GLP-1R and GCGR dual-agonist for recovering hepatic fibrosis
por: Song, Nazi, et al.
Publicado: (2022)

Capparis spinosa improves the high fat diet-induced non-alcoholic steatohepatitis in rats: the possible role of FGF21
por: Akbari, Rasoul, et al.
Publicado: (2020)

Combined Therapy with a CCR2/CCR5 Antagonist and FGF21 Analogue Synergizes in Ameliorating Steatohepatitis and Fibrosis
por: Puengel, Tobias, et al.
Publicado: (2022)

Seed- and leaf-based expression of FGF21-transferrin fusion proteins for oral delivery and treatment of non-alcoholic steatohepatitis
por: Hou, Hsuan-Wu, et al.
Publicado: (2022)

Novel GLP-1 Fusion Chimera as Potent Long Acting GLP-1 Receptor Agonist
por: Wang, Qinghua, et al.
Publicado: (2010)

GLP-1 receptor agonist liraglutide has a neuroprotective effect on an aged rat model of Wolfram syndrome
por: Seppa, Kadri, et al.
Publicado: (2019)

The role of FGF21 in the pathogenesis of cardiovascular disease
por: Zhang, Ying, et al.
Publicado: (2021)

The Cardiovascular Effects of GLP-1 Receptor Agonists
por: Okerson, Theodore, et al.
Publicado: (2012)

GLP-1 Receptor Agonists and Kidney Protection
por: Greco, Eulalia Valentina, et al.
Publicado: (2019)

Clinical Trial Highlights – GLP-1 agonists
por: McFarthing, Kevin, et al.
Publicado: (2020)

Therapeutic Potential of Semaglutide, a Newer GLP-1 Receptor Agonist, in Abating Obesity, Non-Alcoholic Steatohepatitis and Neurodegenerative diseases: A Narrative Review
por: Mahapatra, Manoj K., et al.
Publicado: (2022)

Mesenchymal stem cells modified by FGF21 and GLP1 ameliorate lipid metabolism while reducing blood glucose in type 2 diabetic mice
por: Xue, Binghua, et al.
Publicado: (2021)

Chimeric peptide EP45 as a dual agonist at GLP-1 and NPY2R receptors
por: Chepurny, Oleg G., et al.
Publicado: (2018)

The Emerging Role of Dual GLP-1 and GIP Receptor Agonists in Glycemic Management and Cardiovascular Risk Reduction
por: Rizvi, Ali A, et al.
Publicado: (2022)

Combined ASBT Inhibitor and FGF15 Treatment Improves Therapeutic Efficacy in Experimental Nonalcoholic Steatohepatitis
por: Matye, David J., et al.
Publicado: (2021)

FGF19 and FGF21: In NASH we trust
por: Talukdar, Saswata, et al.
Publicado: (2020)

A Dual GLP-1/GIP Receptor Agonist Is More Effective than Liraglutide in the A53T Mouse Model of Parkinson's Disease
por: Zhang, Zijuan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ras1chntfs7g3k2kodat7ctp8n